92,010 Shares in Exact Sciences Corporation $EXAS Acquired by Syquant Capital Sas

Syquant Capital Sas acquired a new stake in Exact Sciences Corporation (NASDAQ:EXAS) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 92,010 shares of the medical research company’s stock, valued at approximately $9,345,000. Exact Sciences accounts for about 1.1% of Syquant Capital Sas’ portfolio, making the stock its 13th biggest position.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Schaper Benz & Wise Investment Counsel Inc. WI bought a new position in shares of Exact Sciences in the 4th quarter valued at $305,000. Harbor Group Inc. acquired a new stake in shares of Exact Sciences during the 4th quarter valued at $211,000. Assenagon Asset Management S.A. bought a new stake in Exact Sciences during the 4th quarter worth $47,848,000. Marshall Financial Group LLC acquired a new position in Exact Sciences in the 4th quarter worth about $1,794,000. Finally, Fulton Bank N.A. acquired a new position in Exact Sciences in the 4th quarter worth about $278,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Price Performance

Shares of EXAS opened at $104.91 on Friday. The company has a market capitalization of $20.03 billion, a PE ratio of -95.37, a PEG ratio of 2.02 and a beta of 1.41. Exact Sciences Corporation has a 12 month low of $38.81 and a 12 month high of $104.98. The stock’s 50-day moving average price is $103.27 and its two-hundred day moving average price is $87.09. The company has a current ratio of 2.43, a quick ratio of 2.17 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The company had revenue of $878.38 million during the quarter, compared to analyst estimates of $860.59 million. During the same period in the previous year, the company posted ($0.06) EPS. The company’s quarterly revenue was up 23.1% on a year-over-year basis. On average, analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on EXAS. BTIG Research reissued a “neutral” rating on shares of Exact Sciences in a research note on Tuesday. Mizuho reaffirmed a “neutral” rating and issued a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Evercore set a $105.00 price objective on shares of Exact Sciences and gave the company an “in-line” rating in a report on Monday, January 5th. Zacks Research downgraded shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $105.00 target price (up from $80.00) on shares of Exact Sciences in a report on Friday, November 28th. Twenty-one investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $92.13.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.